tetano
Editor, Senior Moderator
NPJ Vaccines
. 2021 Mar 19;6(1):37.
doi: 10.1038/s41541-021-00303-w.
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
Hansam Cho[SUP] #[/SUP][SUP] 1 [/SUP], Yuyeon Jang[SUP] #[/SUP][SUP] 2 3 [/SUP], Ki-Hoon Park[SUP] 2 3 [/SUP], Hanul Choi[SUP] 2 3 [/SUP], Aleksandra Nowakowska[SUP] 3 [/SUP], Hee-Jung Lee[SUP] 3 [/SUP], Minjee Kim[SUP] 3 [/SUP], Min-Hee Kang[SUP] 4 [/SUP], Jin-Hoi Kim[SUP] 4 [/SUP], Ha Youn Shin[SUP] 3 [/SUP], Yu-Kyoung Oh[SUP] 5 [/SUP], Young Bong Kim[SUP] 6 7 8 [/SUP]
Affiliations
Abstract
Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.
. 2021 Mar 19;6(1):37.
doi: 10.1038/s41541-021-00303-w.
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
Hansam Cho[SUP] #[/SUP][SUP] 1 [/SUP], Yuyeon Jang[SUP] #[/SUP][SUP] 2 3 [/SUP], Ki-Hoon Park[SUP] 2 3 [/SUP], Hanul Choi[SUP] 2 3 [/SUP], Aleksandra Nowakowska[SUP] 3 [/SUP], Hee-Jung Lee[SUP] 3 [/SUP], Minjee Kim[SUP] 3 [/SUP], Min-Hee Kang[SUP] 4 [/SUP], Jin-Hoi Kim[SUP] 4 [/SUP], Ha Youn Shin[SUP] 3 [/SUP], Yu-Kyoung Oh[SUP] 5 [/SUP], Young Bong Kim[SUP] 6 7 8 [/SUP]
Affiliations
- PMID: 33741992
- DOI: 10.1038/s41541-021-00303-w
Abstract
Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.